ABBV200918C00032500
| Previous Close | 34.50 |
| Open | N/A |
| Bid | 41.80 |
| Ask | 42.80 |
| Strike | N/A |
| Expire Date | 2020-09-18 |
| Day's Range | N/A - N/A |
| Contract Range | N/A |
| Volume | N/A |
| Open Interest | N/A |
- Zacks
3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019 (Revised)
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
- Zacks
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019 (Revised)
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
- Investor's Business Daily
Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020
Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Gene therapy and oncology companies are targets.
- Zacks
Retirees Should Know These 3 Facts About Required Minimum Distributions - December 13, 2019
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
- Barrons.com
Walgreens, AbbVie, and 3 Other Dividend Aristocrat Stocks That Have Lagged the Market This Year
The S&P 500 Dividend Aristocrats—the companies which have raised their dividends for at least 25 straight years—are known for their durability, especially in a difficult market. For example, in last year’s tumultuous fourth quarter, with the S&P 500 down 13.5%, the Aristocrats fell 8.6%. 2019 has hardly been tough for stocks, with the S&P 500 having returned about 26%.
- GuruFocus.com
Seattle Genetics' Cancer Study Boosts Prospects, Takeover Appeal
Needham analyst raises target price after promising results of drug trial Continue reading...
AbbVie's 2019 Points to the End of the Efficient Market Thesis - Cramer
Jim Cramer sees the market's reaction to AbbVie's purchase of Allergan as an example of its move away from valuing fundamentals and instead getting bogged down in the noise.
- Zacks
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
- Zacks
3 Investing Facts About Required Minimum Distributions You Need to Know - December 12, 2019
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
- Simply Wall St.
Should We Worry About AbbVie Inc.'s (NYSE:ABBV) P/E Ratio?
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E...
- Zacks
Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - December 11, 2019
Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.
- Zacks
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants
Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.
- Zacks
Top Research Reports for Novartis, AbbVie & Sanofi
Top Research Reports for Novartis, AbbVie & Sanofi
- Zacks
Biotech ETFs Hit New Highs on Deal Activities
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
- Investor's Business Daily
Merck Stock Is On An Upswing In 2019 — Should You Buy This Pharma Stock?
Merck stock is on an upswing with a 14% gain in the first 11 full months of 2019. Meanwhile shares of other pharma companies grabbed a smaller gain. Is it time to give MRK stock a shot?
- Zacks
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $86.43, marking a -0.63% move from the previous day.
- Zacks
J&J Presents Data on CAR-T Therapy Drug and Imbruvica at ASH
J&J's (JNJ) initial data on CAR-T therapy candidate JNJ-68284528 from an early-stage study shows promising response rate.
- American City Business Journals
World's largest biotech company to move up to BioMed's big South City project
The biotech company acquired its first Bay Area presence 15 years ago; now it's planning to move into a high-profile biotech-focused project.
- Zacks
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
- Zacks
3 Top Dividend Stocks to Maximize Your Retirement Income - December 09, 2019
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
- GlobeNewswire
Adaptive and AbbVie Partner Across Multiple Myeloma Trials to Measure Minimal Residual Disease Using the clonoSEQ® Assay
Adaptive Biotechnologies Corporation (ADPT) today announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) status in response to venetoclax across multiple myeloma (MM) clinical trials. “Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment.
- PR Newswire
AbbVie and Scripps Research announce collaboration to develop a broad range of new therapeutics
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company and Scripps Research, an international leader in non-profit biomedical research and drug discovery, today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis.
- PR Newswire
New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today presented long-term data from a post-hoc analysis, further supporting the sustained clinical benefit of fixed duration treatment with VENCLEXTA®/VENCLYXTO® (venetoclax) in combination with rituximab (VenR) in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). The updated data from the Phase 3 MURANO trial four-year analysis (median follow-up of 48 months with all patients off VENCLEXTA/VENCLYXTO treatment for a median of 22 months) showed that patients with R/R CLL who completed the chemotherapy-free, two-year fixed duration course of VENCLEXTA/VENCLYXTO treatment combination maintained progression-free survival (PFS) and overall survival (OS). Patients who completed treatment with the VENCLEXTA/VENCLYXTO combination also achieved higher rates of minimal residual disease (MRD)-negativity and complete remissions compared to those treated with a standard of care, bendamustine plus rituximab (BR).1 The full results were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (abstract 355).
- PR Newswire
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results of a 7.5-year pooled analysis showing earlier treatment with IMBRUVICA® (ibrutinib) monotherapy compared to later lines of therapy (LOT) extended progression-free survival (PFS) and increased the likelihood of a complete response (CR) in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) – demonstrating that some patients achieved a disappearance of any signs of disease.
- PR Newswire
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced results from an extended follow-up analysis of the Phase 3 E1912 clinical study – designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), which is part of the National Institutes of Health. Study results showed superior progression-free survival (PFS) and overall survival (OS) in patients with chronic lymphocytic leukemia (CLL) new to treatment.
